Joe McCann
Contributor since: 2014
Company: Slingshot insights
Latest Articles
Financial Exchange Stock Talk: Joe McCann On Amarin
Financial Exchange Stock Talk: Joe McCann On Loxo Oncology And bluebird bio
Financial Exchange Stock Talk: Joe McCann On Loxo Oncology
Financial Exchange Stock Talk: Joe McCann On Selecta Biosciences
Financial Exchange Stock Talk: Joe McCann On Amazon, Berkshire Hathaway And JPMorgan's Foray Into Healthcare
Amazon Doing What It Does Best - Slingshot Insights' Joe McCann's Idea Of The Month
Why Keeping Up With FDA Approvals Could Help Your Stock Portfolio - Slingshot Insights' Joe McCann's Idea Of The Month
Does Tonix's Lead Drug Candidate TNX-102 SL Have What It Takes To Treat PTSD, And If So, Just How Big Is The Market?
This Week In Pharma: Keryx's Sluggish Drug Launch Vs. Excitement At Valeant And Palatin
This Week In Pharma: Xoma's Big Day And Dyax Vs. BioCryst Vs. Shire - Who Will Own HAE?
Synergy Is Worth $25 / Share As Plecanatide Is Set To Be A Blockbuster In An Underserved Market
This Week In Pharma: Controversies And Revelations About Synergy And Zogenix
Genocea's GEN-003 Reviewed By An Immunologist- This Week In Pharma Controversies Investigated
This Week In Pharma: Controversies, Revelations, And Data That Needs To Be Questioned
Exact Sciences: Revisiting Cologuard's Value
Despite The Sell-Off, Zohydro Is A Falling Knife Too Dangerous To Catch
InterMune's A Strong Buy As Esbriet Finally Has The Data Physicians, Patients, And FDA Have Longed For
Cologuard Will Dominate Its Addressable Market
Zohydro's Chances Of Staying On The Market